# A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

> **NCT05465785** · NA · COMPLETED · sponsor: **WestVac Biopharma Co., Ltd.** · enrollment: 1000 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Pneumonia

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 vaccine (Sf9 cell)

## Key facts

- **NCT ID:** NCT05465785
- **Lead sponsor:** WestVac Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-20
- **Primary completion:** 2023-03-11
- **Final completion:** 2023-12-30
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465785, "A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05465785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*